Achieve Life Sciences ACHV
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Achieve Life Sciences (ACHV)
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Key Insights
Critical company metrics and information
Latest Closing Price
$3.14Market Cap
$107.98 MillionPrice-Earnings Ratio
-8.72Total Outstanding Shares
34.39 Million SharesTotal Employees
22Dividend
No dividendIPO Date
October 12, 1995SIC Description
In Vitro & In Vivo Diagnostic SubstancesPrimary Exchange
NASDAQType
Common StockHeadquarters
22722 29th dr. se, Seattle, WA, 98021Homepage
https://www.achievelifesciences.com
Historical Stock Splits
If you bought 200 shares of ACHV before May 24, 2018, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| July 31, 2020 | 1-for-20 (Reverse Split) |
| May 24, 2018 | 1-for-10 (Reverse Split) |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $-8.11 Million |
| Net Cash Flow From Investing Activities | $13.27 Million |
| Net Cash Flow From Financing Activities, Continuing | $-8.11 Million |
| Net Cash Flow From Investing Activities, Continuing | $13.27 Million |
| Net Cash Flow From Operating Activities, Continuing | $-10.37 Million |
| Net Cash Flow From Operating Activities | $-10.37 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-12.51 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Diluted Earnings Per Share | $-0.36 |
| Diluted Average Shares | $34.36 Million |
| Nonoperating Income/Loss | $-46,000 |
| Depreciation and Amortization | $57,000 |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-12.43 Million |
| Other Comprehensive Income/Loss | $82,000 |
| Comprehensive Income/Loss Attributable To Parent | $-12.43 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Assets | $47.92 Million |
| Equity Attributable To Parent | $31.38 Million |
| Wages | $2.34 Million |
| Liabilities And Equity | $47.92 Million |
| Equity | $31.38 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ACHV from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.